Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy Followed by TORS for Oropharyngeal Cancer
NCT04277858Phase 2Recruiting
- Start
- Aug 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in oropharyngeal squamous cell carcinoma (OPSCC). Primary endpoint: Progression Free Survival at 2 years. Started Aug 2018; status: recruiting.
02
Drugs
docetaxel
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04277858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277858.